<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CrashDash ‚Ä¢ GDR.L APEX Profile</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { 
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 20px;
            color: #333;
        }
        .container { max-width: 1200px; margin: 0 auto; }
        
        .header-card {
            background: white;
            border-radius: 16px;
            padding: 30px;
            margin-bottom: 20px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }
        .ticker-badge {
            display: inline-block;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 8px 16px;
            border-radius: 20px;
            font-weight: bold;
            font-size: 18px;
            margin-bottom: 10px;
        }
        .company-name { font-size: 32px; font-weight: 700; margin-bottom: 8px; }
        .company-meta {
            display: flex;
            gap: 20px;
            margin-top: 15px;
            flex-wrap: wrap;
        }
        .meta-item {
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: #f7fafc;
            border-radius: 8px;
            font-size: 14px;
        }
        .meta-icon { font-size: 18px; }
        
        .score-hero {
            background: linear-gradient(135deg, #6b7280 0%, #4b5563 100%);
            color: white;
            border-radius: 16px;
            padding: 40px;
            margin-bottom: 20px;
            text-align: center;
            box-shadow: 0 10px 40px rgba(0,0,0,0.15);
        }
        .action-display {
            margin-bottom: 20px;
        }
        .scores-row {
            display: flex;
            justify-content: center;
            gap: 40px;
            margin: 30px 0;
        }
        .score-circle {
            width: 140px;
            height: 140px;
            border-radius: 50%;
            background: white;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }
        .score-number {
            font-size: 48px;
            font-weight: 800;
            line-height: 1;
        }
        .score-label { font-size: 12px; color: #666; margin-top: 5px; }
        .timing-badge-large {
            display: inline-block;
            padding: 15px 40px;
            border-radius: 30px;
            font-weight: 700;
            font-size: 24px;
            background: rgba(255,255,255,0.2);
            backdrop-filter: blur(10px);
            color: white;
            margin: 20px 0;
        }
        .thesis-line {
            font-size: 18px;
            font-weight: 600;
            color: white;
            background: rgba(255,255,255,0.15);
            backdrop-filter: blur(10px);
            padding: 20px;
            border-radius: 12px;
            margin-top: 20px;
        }
        
        .factors-list {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 15px;
            margin-top: 20px;
        }
        .factor-item {
            background: white;
            padding: 15px;
            border-radius: 12px;
            display: flex;
            align-items: center;
            gap: 10px;
            font-size: 14px;
        }
        .factor-icon { font-size: 20px; }
        
        .cards-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 20px;
        }
        .card {
            background: white;
            border-radius: 16px;
            padding: 25px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
        }
        .card-title {
            font-size: 18px;
            font-weight: 600;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        .card-icon { font-size: 24px; }
        
        .stat-row {
            display: flex;
            justify-content: space-between;
            padding: 12px 0;
            border-bottom: 1px solid #f0f0f0;
        }
        .stat-row:last-child { border-bottom: none; }
        .stat-label { color: #666; font-size: 14px; }
        .stat-value { font-weight: 600; font-size: 16px; }
        
        .rally-badge {
            display: inline-block;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
        }
        
        .risk-indicator {
            display: flex;
            align-items: center;
            gap: 15px;
            padding: 15px;
            border-radius: 12px;
            margin-bottom: 10px;
        }
        .risk-high { background: #fee2e2; }
        .risk-icon { font-size: 24px; }
        
        .reason-item {
            padding: 15px;
            background: #f9fafb;
            border-radius: 8px;
            margin-bottom: 12px;
        }
        
        .tag {
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
        }
        
        .footer {
            background: white;
            border-radius: 16px;
            padding: 20px;
            text-align: center;
            color: #666;
            font-size: 13px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
            margin-top: 20px;
        }
        
        .alert-box {
            background: #fef3c7;
            border-left: 4px solid #f59e0b;
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
        }
    </style>
</head>
<body>
    <div class="container">
        
        <!-- Header Card -->
        <div class="header-card">
            <div class="ticker-badge">GDR.L</div>
            <div class="company-name">genedrive plc</div>
            <div class="company-meta">
                <div class="meta-item">
                    <span class="meta-icon">‚ñ†</span>
                    <span><strong>Sector:</strong> Healthcare</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">¬£</span>
                    <span><strong>Market Cap:</strong> ¬£9,009,034</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">‚ó∑</span>
                    <span><strong>Days Active:</strong> 94 days</span>
                </div>
            </div>
        </div>

        <!-- Action & Score Hero Section -->
        <div class="score-hero">
            <div class="action-display">
                <span style="color: white;">UNKNOWN</span>
            </div>
            
            <div class="scores-row">
                <div class="score-circle">
                    <div class="score-number" style="color: #f59e0b;">53</div>
                    <div class="score-label">APEX SCORE</div>
                </div>
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">40</div>
                    <div class="score-label">CONFIDENCE</div>
                </div>
            </div>
            
            <div class="timing-badge-large">
                Timing: <span class="rally-badge" style="background: #dcfce7; color: #166534;">CONFIRMED</span>
            </div>
            
            <div class="thesis-line">
                HOLD/WATCH - CONFIRMED timing with 53/100 opportunity score
            </div>
        </div>

        <!-- ==================== AI TRADER INTELLIGENCE (TOP) - TRADER BRIEF V2 ==================== -->
        

        <!-- Decision Summary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óÜ</span>
                Why This Matters
            </div>
            <div class="stat-row"><span>‚Ä¢ APEX 53/100 indicates strong opportunity quality</span></div><div class="stat-row"><span>‚Ä¢ Timing regime: CONFIRMED</span></div><div class="stat-row"><span>‚Ä¢ Historical profile: 1 rallies, 312% best run</span></div>
            
            <div class="alert-box" style="margin-top: 20px;">
                <strong>‚ñ≥ Main Risk:</strong> Confidence 40/100 - full data loaded
            </div>
            
            <div style="margin-top: 20px;">
                <strong>‚óâ Watch Next:</strong>
                <div style="padding: 8px 0;">‚Ä¢ RNS catalysts (funding/operational updates)</div><div style="padding: 8px 0;">‚Ä¢ Volume expansion confirmation</div><div style="padding: 8px 0;">‚Ä¢ Timing regime change signals</div>
            </div>
        </div>

        <!-- ==================== TECHNICAL DETAILS (COLLAPSIBLE) ==================== -->
        
        <div class="card">
          <details style="cursor:pointer;">
            <summary style="font-weight:800; font-size:16px; list-style:none; padding: 10px; background: #f9fafb; border-radius: 8px;">
              üîß Technical Analysis & Scoring Details
            </summary>
            <div style="margin-top:14px;">
              
            <!-- Scoring Breakdown -->
            <div class="card-title" style="margin-top: 20px;">
                <span class="card-icon">‚ñ£</span>
                APEX Score Breakdown
            </div>
            <div class="factors-list">
                <div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Strong Technical Setup</strong><br><small>Chart quality: 10/20 ‚Ä¢ Score: 12/25 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Massive recovery potential</strong><br><small>Down 91.5% from peak ‚Ä¢ Score: 18/20 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Above average volume</strong><br><small>1.5x average ‚Ä¢ Score: 6/10 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Limited history</strong><br><small>1 previous rallies ‚Ä¢ Score: 5/15 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Major upside</strong><br><small>Historical best: +312% ‚Ä¢ Score: 12/20 points</small></span></div>

            </div>
            
            <div style="margin-top: 40px;"></div>
            
            <!-- Exhaustion Metrics -->
            <div class="card-title">
                <span class="card-icon">üìà</span>
                Rally Cycle Position
            </div>
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 15px; margin: 20px 0;">
                <div style="padding: 15px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Current Position</div>
                    <div style="font-size: 32px; font-weight: 800;">243%</div>
                    <div style="font-size: 11px; opacity: 0.8;">from entry</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #3b82f6 0%, #1d4ed8 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Typical Rally</div>
                    <div style="font-size: 32px; font-weight: 800;">312%</div>
                    <div style="font-size: 11px; opacity: 0.8;">historical avg</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #f59e0b 0%, #d97706 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Exhaustion Level</div>
                    <div style="font-size: 32px; font-weight: 800;">0.8x</div>
                    <div style="font-size: 11px; opacity: 0.8;">vs average</div>
                </div>
            </div>
        
            </div>
          </details>
        </div>
        

        <!-- Reasons Buy/Sell -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #10b981;">‚ñ≤</span>
                    Reasons to Buy
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Proven winner - previously hit lock-in target</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">profit target reached: True</div>
            </div>
            
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #ef4444;">‚ñº</span>
                    Reasons to Sell / Avoid
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Triangulation not loaded (RNS/social/trends missing)</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">HISTORICAL ONLY ‚Ä¢ confidence capped at 65</div>
            </div>
            
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Stale signal - not for active trading</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">historical</div>
            </div>
            
            </div>
        </div>

        <!-- Trade Plans -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üìä</span>
                    Short-Term Trader Playbook
                </div>
                <div style="background: linear-gradient(135deg, #f093fb 0%, #f5576c 20%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px;">
                    <div style="font-size: 18px; font-weight: 600; margin-bottom: 5px;">Active trade</div>
                    <div style="font-size: 14px; opacity: 0.9;">HOLD/WATCH</div>
                </div>
                <div style="padding: 12px; background: #f9fafb; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Position Size</div>
                    <div style="font-weight: 600;">1-3% position based on conviction</div>
                </div>
                <div style="padding: 12px; background: #fef2f2; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Risk Management</div>
                    <div style="font-weight: 600; color: #dc2626;">Stop below recent support / invalidation level</div>
                </div>
                <div style="padding: 12px; background: #f0fdf4; border-radius: 6px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Exit Strategy</div>
                    <div style="font-weight: 600; color: #059669;">Scale out into strength: 25% @ +15%, 50% @ +50%, trail runner</div>
                </div>
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üíº</span>
                    Long-Term Investor Playbook
                </div>
                <div style="background: linear-gradient(135deg, #667eea 0%, #764ba2 100%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px; text-align: center;">
                    <div style="font-size: 32px; margin-bottom: 5px;">‚úó</div>
                    <div style="font-size: 18px; font-weight: 600;">Not Recommended for Investors</div>
                </div>
                <div style="padding: 15px; background: #f9fafb; border-radius: 8px; font-size: 14px; line-height: 1.6;">
                    <strong style="color: #667eea;">üìã Investment Thesis:</strong><br>
                    Unlock after AI triangulation + CONFIRMED timing<br><br>
                    <strong style="color: #667eea;">‚è≥ Time Horizon:</strong><br>
                    N/A<br><br>
                    <strong style="color: #ef4444;">üõ°Ô∏è Exit Rule:</strong><br>
                    N/A
                </div>
            </div>
        </div>

        <!-- Commentary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óê</span>
                Executive Commentary
            </div>
            <div style="line-height: 1.6; margin-bottom: 20px;">
                This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows CONFIRMED timing with 53/100 APEX score. Historical data shows 1 rallies averaging 312% upside. Current position: +243.1%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #10b981;">‚ñ≤ Bull Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Limited upside case without catalysts</div>
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #ef4444;">‚ñº Bear Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Monitor for breakdown signals</div>
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #f0f9ff; border-radius: 8px;">
                <strong>‚ó∑ Timing Translation:</strong><br>
                Momentum confirmed. This is the trade zone if thesis holds.
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #fef3c7; border-radius: 8px;">
                <strong>‚óé Confidence Explained:</strong><br>
                Confidence 40/100 reflects full data quality with triangulation loaded.
            </div>
        </div>

        <!-- Data Quality Warning -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚ñ≥</span>
                Data Quality Notice
            </div>
            <div class="alert-box">
                <strong>Analysis Mode:</strong> HISTORICAL_ONLY<br>
                <strong>Impact:</strong> HIGH
            </div>
            <div class="risk-indicator risk-high"><span class="risk-icon">‚ñ≥</span><div><div style="font-weight: 600;">AI insights from Groq LLM</div></div></div>

            <div style="margin-top: 15px; font-size: 13px; color: #666;">
                Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk.
            </div>
        </div>

        <!-- ==================== TOP 5 RECENT RNS NEWS ==================== -->
        
        <div class="card" style="border-top: 3px solid #3b82f6;">
            <div class="card-title" style="margin-bottom: 20px;">
                <span class="card-icon">üì∞</span>
                Top 5 Recent RNS Announcements
            </div>
            <div style="margin-top: 15px;">
                
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #10b98140;
                    ">1</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #1
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìà</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Result of AGM</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 90/100 ‚Ä¢ BULLISH</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    FINANCIAL RESULTS: Financial results released | ‚úÖ BULLISH: Positive results typically drive price increases. Check guidance for future expectations.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">31st Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">11:44 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">BULLISH</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #10b981;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #10b981;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">90/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">FINANCIAL RESULTS: Financial results released</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #10b981; font-weight: 600;">‚úÖ BULLISH: Positive results typically drive price increases. Check guidance for future expectations.</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚û°Ô∏è STABLE: Mixed signals, normal operations</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Primary Information</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">96.3%, 3.7%, 92.5%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
31 Dec 2025 11:44
RNS Number : 3308N
Genedrive PLC
31 December 2025
genedrive plc
("genedrive" or the "Company")
Result of AGM
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company,
announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.
For information, details of the proxy voting are shown below:
Resolution
Votes For
Votes For(as % of votes cast)
Votes Against
Votes Against(as % of votes cast)
Vote Withheld
1
300,517,371
96.3%
11,462,340
3.7%
310,795
2
279,601,700
92.5%
22,748,568
7.5%
9,940,238
3
274,303,174
87.9%
37,630,181
12.1%
357,151
4
277,003,174
88.9%
34,426,121
11.1%
861,211
5
273,385,392
87.6%
38,602,300
12.4%
302,814
6
278,647,955
91.2%
26,907,325
8.8%
6,735,226
7
265,095,868
85.1%
46,474,234
14.9%
720,404
8
285,423,686
93.4%
20,077,227
6.6%
6,789,593
9
274,147,003
89.8%
31,020,884
10.2%
7,122,619
10
278,146,034
91.4%
26,267,600
8.6%
7,876,872
11
278,179,297
91.4%
26,234,367
8.6%
7,876,842
The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (
www.genedrive.com
).
Engage with the genedrive management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
hub here:
https://investors.genedrive.com/link/PZ3d7y
For further details please contact:
Genedrive plc
Dr Gino Miele (CEO)
Russ Shaw (CFO)
We encourage all investors to share questions
on this announcement via our investor hub
https://investors.genedrive.com/s/e0025c
+44 (0) 161 989 0245
Peel Hunt LLP - Nominated Adviser, Joint Broker
James Steel
+44 (0) 20 7148 8900
Walbrook PR Ltd (Media & Investor Relations)
Anna Dunphy
https://investors.genedrive.com/s/e0025c
+44 (0)20 7933 8780 or
genedrive@walbrookpr.com
+44 (0)7876 741 001
Subscribe to our news alert service:
https://investors.genedrive.com/s/efea03
About genedrive plc
(
http://www.genedrive.com
)
genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive¬Æ MT-RNR1 ID Kit and the Genedrive¬Æ CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive¬Æ MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
RAGBBBDDGSXDGUB
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #10b98140;
                    ">2</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #2
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìà</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Result of AGM</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 90/100 ‚Ä¢ BULLISH</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    FINANCIAL RESULTS: Financial results released | ‚úÖ BULLISH: Positive results typically drive price increases. Check guidance for future expectations.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">31st Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">11:44 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">BULLISH</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #10b981;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #10b981;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">90/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">FINANCIAL RESULTS: Financial results released</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #10b981; font-weight: 600;">‚úÖ BULLISH: Positive results typically drive price increases. Check guidance for future expectations.</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚û°Ô∏è STABLE: Mixed signals, normal operations</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Primary Information</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">96.3%, 3.7%, 92.5%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
31 Dec 2025 11:44
RNS Number : 3308N
Genedrive PLC
31 December 2025
genedrive plc
("genedrive" or the "Company")
Result of AGM
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company,
announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.
For information, details of the proxy voting are shown below:
Resolution
Votes For
Votes For(as % of votes cast)
Votes Against
Votes Against(as % of votes cast)
Vote Withheld
1
300,517,371
96.3%
11,462,340
3.7%
310,795
2
279,601,700
92.5%
22,748,568
7.5%
9,940,238
3
274,303,174
87.9%
37,630,181
12.1%
357,151
4
277,003,174
88.9%
34,426,121
11.1%
861,211
5
273,385,392
87.6%
38,602,300
12.4%
302,814
6
278,647,955
91.2%
26,907,325
8.8%
6,735,226
7
265,095,868
85.1%
46,474,234
14.9%
720,404
8
285,423,686
93.4%
20,077,227
6.6%
6,789,593
9
274,147,003
89.8%
31,020,884
10.2%
7,122,619
10
278,146,034
91.4%
26,267,600
8.6%
7,876,872
11
278,179,297
91.4%
26,234,367
8.6%
7,876,842
The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (
www.genedrive.com
).
Engage with the genedrive management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
hub here:
https://investors.genedrive.com/link/PZ3d7y
For further details please contact:
Genedrive plc
Dr Gino Miele (CEO)
Russ Shaw (CFO)
We encourage all investors to share questions
on this announcement via our investor hub
https://investors.genedrive.com/s/e0025c
+44 (0) 161 989 0245
Peel Hunt LLP - Nominated Adviser, Joint Broker
James Steel
+44 (0) 20 7148 8900
Walbrook PR Ltd (Media & Investor Relations)
Anna Dunphy
https://investors.genedrive.com/s/e0025c
+44 (0)20 7933 8780 or
genedrive@walbrookpr.com
+44 (0)7876 741 001
Subscribe to our news alert service:
https://investors.genedrive.com/s/efea03
About genedrive plc
(
http://www.genedrive.com
)
genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive¬Æ MT-RNR1 ID Kit and the Genedrive¬Æ CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive¬Æ MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
RAGBBBDDGSXDGUB
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">3</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #3
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Scotland NHS ‚Äútest of change‚Äù pilot programme</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 70/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    CORPORATE NEWS: Scotland NHS ‚Äútest of change‚Äù pilot programme | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">18th Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">70/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">CORPORATE NEWS: Scotland NHS ‚Äútest of change‚Äù pilot programme</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚û°Ô∏è STABLE: Mixed signals, normal operations</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Primary Information</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
18 Dec 2025 07:00
RNS Number : 0225M
Genedrive PLC
18 December 2025
genedrive plc
("genedrive" or the "Company")
Genedrive's CYP2C19 ID kit piloted as a "test of change" in Scotland NHS Grampian and Western Isles
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that Genedrive's CYP2C19 ID Kit has been implemented into Scottish NHS Grampian (Dr. Gray's Hospital, Elgin) & NHS Western Isles (Western Isles Hospital, Stornoway) under a "test of change" pilot programme for stroke patients in remote and rural settings.
Whilst the pathway for CYP2C19 genotyping in NHS Scotland currently relies on laboratory testing, the Centre For Sustainable Delivery, commissioned by the Scottish Government, are assessing the impact of rapid genetic testing using the Genedrive CYP2C19 ID kit under a "test of change" programme which will run for approximately one year and include c.400 patients.
Further details are available at
https://shorturl.at/P4i00
Dr Gino Miele, CEO of genedrive plc, said:
"We are delighted that the Centre for Sustainable Delivery is assessing the impact of our interventional rapid genetic test solution in NHS Grampian and Western Isles, enabling a precision medicine approach to antiplatelet therapy in these stroke patients in rural settings, and ultimately, significantly better outcomes for patients in these communities. Whilst a relatively small "pilot" programme, it is notable that our interventional test is being explored as a "test of change" and we are confident that the clinical value of our rapid testing solution will continue to be evident and the case for wider deployment in Scotland strengthened."
NHS Grampian consultant in stroke/acute medicine and clinical lead for the project, Petrus Elofuke, said:
"
We are introducing the Genedrive¬Æ CYP2C19 ID Kit test as a test of change in Elgin and Stornoway at the same time as samples are sent for lab-based testing. We'll look at how results compare over the next year. It's the first time a device of this kind has been tested in remote and rural settings, and we're extremely proud to be working with colleagues across the two health boards as well as the national Centre for Sustainable Delivery."
Clinical lead for the project in NHS Western Isles, David Rigby said:
"If the devices deliver proven results over the next year, then our project will inform the business case for revolutionising stroke care for remote and rural patients across Scotland. The Genedrive¬Æ devices are the size of a small shoe box and are easily accommodated in smaller rural hospitals. We are very pleased to be working closely alongside manufacturers Genedrive Diagnostics Ltd and providing huge benefit to local patients as we make the case for wider use of this exciting new tech."
Jason White the Head of Innovation in the Accelerated National Innovation Adoption (ANIA) team which is part of the NHS National Centre for Sustainable Delivery, said:
"This project is a powerful example of how innovation can directly improve patient care, especially in remote and rural communities. By enabling rapid genetic testing at the point of care, we're helping clinicians make faster, more informed decisions about stroke treatment. It's about delivering the right care, in the right place, at the right time and we're proud to support this collaborative effort through the ANIA pathway."
Engage with the genedrive management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
hub here:
https://investors.genedrive.com/link/PZ3d7y
For further information, please contact:
Genedrive plc
Dr Gino Miele (CEO)
Russ Shaw (CFO)
We encourage all investors to share questions
on this announcement via our investor hub
https://investors.genedrive.com/s/e0025c
+44 (0) 161 989 0245
Peel Hunt LLP - Nominated Adviser, Joint Broker
James Steel
+44 (0) 20 7148 8900
Walbrook PR Ltd (Media & Investor Relations)
Anna Dunphy
https://investors.genedrive.com/s/e0025c
+44 (0)20 7933 8780 or
genedrive@walbrookpr.com
+44 (0)7876 741 001
Subscribe to our news alert service:
https://investors.genedrive.com/s/efea03
About genedrive plc (http://www.genedrive.com)
genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive¬Æ MT-RNR1 ID Kit and the Genedrive¬Æ CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive¬Æ MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
MSCEANAXFDPSFFA
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">4</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #4
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">New interactive investor hub</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 75/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    CORPORATE NEWS: New interactive investor hub | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">11th Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">9:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">75/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">CORPORATE NEWS: New interactive investor hub</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚û°Ô∏è STABLE: Mixed signals, normal operations</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Primary Information</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
11 Dec 2025 09:00
RNS Number : 1846L
Genedrive PLC
11 December 2025
genedrive plc
("genedrive" or the "Company")
genedrive plc launches new interactive investor hub
genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, is pleased to announce the launch of our interactive investor hub. For both existing and prospective shareholders, over time the new investor hub will bring all genedrive content into a single integrated platform to better inform and engage with investors and stakeholders.
The investor hub provides an interactive online experience allowing genedrive stakeholders to comment on and ask the genedrive team questions via a portal which will be monitored and responded to as timely as possible.
How to sign up for the genedrive investor hub:
1. Visit
investors.genedrive.com
2. Follow the prompts to sign up for an investor hub account
3. Complete your account profile
Dr Gino Miele, CEO of genedrive plc, said:
"Open and transparent communication with our shareholders is essential, particularly in a fast-moving environment like ours. Whilst RNS remains the first source of regulated news on genedrive, the investor hub gives us a direct channel to share accurate information and meaningful updates straight from the company ensuring investors hear from us directly. The hub enables shareholders to submit questions, receive updates, and engage directly with the Company. We encourage all investors to register and use the hub as their central source for trusted updates, insights, and dialogue with our team."
Engage with the genedrive management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
hub here:
https://investors.genedrive.com/link/PZ3d7y
For further information, please contact:
Genedrive plc
Dr Gino Miele (CEO)
Russ Shaw (CFO)
We encourage all investors to share questions
on this announcement via our investor hub
https://investors.genedrive.com/s/e0025c
+44 (0) 161 989 0245
Peel Hunt LLP - Nominated Adviser, Joint Broker
James Steel
+44 (0) 20 7148 8900
Walbrook PR Ltd (Media & Investor Relations)
Anna Dunphy
https://investors.genedrive.com/s/e0025c
+44 (0)20 7933 8780 or
genedrive@walbrookpr.com
+44 (0)7876 741 001
Subscribe to our news alert service:
https://investors.genedrive.com/s/efea03
About genedrive plc (
http://www.genedrive.com
)
genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive¬Æ MT-RNR1 ID Kit and the Genedrive¬Æ CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive¬Æ MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
MSCUAUWRVBUUARA
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">5</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #5
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Agreement of Shareholder Loan</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 75/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    CORPORATE NEWS: Agreement of Shareholder Loan | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">9th Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">3:45 pm</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">75/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">CORPORATE NEWS: Agreement of Shareholder Loan</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚û°Ô∏è STABLE: Mixed signals, normal operations</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Primary Information</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
9 Dec 2025 15:45
RNS Number : 8874K
Genedrive PLC
09 December 2025
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION) AS RETAINED AS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.
UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
genedrive plc
("genedrive" or the "Company")
Agreement of Shareholder Loan
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that further to the announcement of 19 November 2025 confirming that heads of term had been agreed for a potential shareholder loan (the "Loan") from David Nugent, a significant shareholder in the Company, the Company is pleased to confirm today that definitive agreements have now been signed for the Loan.
Further terms of the Loan and Related Party Transaction
The Company and David Nugent have entered into a Loan Agreement for up to ¬£1.0 million in value (the "Loan"). The Loan is available to be drawn in two equal tranches of ¬£500,000. The first tranche shall be requested imminently and shall not attract any commitment fee, interest or charges. The first tranche is expected to extend the Company's cash runway into February 2026. The second tranche will be available to be drawn down at the request and discretion of the Company on or after 20 February 2026 (or such other date as may be agreed between the Company and David Nugent). Draw down of the second tranche would incur a fixed fee of ¬£50,000 which shall be added to the amount of principal and would need to be repaid upon repayment or conversion of the second tranche. The loan shall be secured by the grant of a debenture over all the Company's assets and is for a maximum period of twelve months. David Nugent currently intends that all amounts of the Loan drawn down shall be converted into equity as part of a future equity raise.
David Nugent is a related party of the Company pursuant to the AIM Rules and him being a party to the Loan constitutes a related party transaction for the purposes of AIM Rule 13. The Directors consider, having consulted with the Company's nominated adviser, Peel Hunt LLP, that the Company entering to the Loan with David Nugent is fair and reasonable insofar as Shareholders are concerned.
Dr Gino Miele, CEO of genedrive plc, said:
"On behalf of the Company I extend my gratitude to David for providing this Loan on the terms now agreed. The Loan provides a valuable extension to our cash runway whist we continue to execute against our commercial and strategic goals and work towards longer term financing options."
Mr David Nugent, said:
"I am delighted to provide this Loan to the Company as I am determined to ensure that the Company has the financial and other resources it needs to deliver for both patients and shareholders. As a significant shareholder in the Company I am also encouraged by the recent progress within genedrive which has coincided with a significant recovery in the Company's share price and I intend to provide further financial support to the Company going forwards."
For further details please contact:
genedrive plc
+44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser and Broker)
+44 (0)20 7418 8900
James Steel
Walbrook PR Ltd (Media & Investor Relations)
+44 (0)20 7933 8780 or
genedrive@walbrookpr.com
Anna Dunphy
+44 (0)7876 741 001
About genedrive plc (
http://www.genedrive.com
)
genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive¬Æ MT-RNR1 ID Kit and the Genedrive¬Æ CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive¬Æ MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
AGRPKCBQPBDDBBK
                </div>
            </details>
            
            </div>
            
            </div>
            <div style="
                margin-top: 20px;
                padding: 14px 16px;
                background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
                border-radius: 10px;
                font-size: 12px;
                color: #78350f;
                border-left: 3px solid #f59e0b;
                display: flex;
                align-items: flex-start;
                gap: 10px;
            ">
                <span style="font-size: 16px; margin-top: 2px;">üéØ</span>
                <div style="line-height: 1.5;">
                    <strong style="display: block; margin-bottom: 4px;">Trader-Focused Analysis:</strong>
                    Each RNS includes sentiment classification, key data extraction, and trading context. 
                    Color-coded badges indicate bullish (green), bearish (red), or neutral (blue) signals.
                    <strong style="margin-top: 6px; display: block; font-size: 10px; opacity: 0.8;">
                    ‚ö†Ô∏è This is analysis of regulatory news for informational purposes. Not investment advice.
                    </strong>
                </div>
            </div>
        </div>
        
        <style>
            @keyframes slideDown {
                from {
                    opacity: 0;
                    transform: translateY(-10px);
                }
                to {
                    opacity: 1;
                    transform: translateY(0);
                }
            }
            details[open] > summary {
                background: linear-gradient(135deg, #eff6ff 0%, #f0f9ff 100%) !important;
                border-left-color: #0369a1 !important;
            }
            summary::-webkit-details-marker {
                display: none;
            }
        </style>
        

        <!-- Footer -->
        <div class="footer">
            Report generated: 2026-01-12 ‚Ä¢ CrashDash APEX Engine<br>
            <strong>‚ñ≥ Not financial advice. Do your own research.</strong>
        </div>

    </div>
</body>
</html>